Roots of clinical resistance to STI-571 cancer therapy.
Hochhaus
A
A
III. Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, Mannheim, Germany. hochhaus@uni-hd.de
Kreil
S
S
Corbin
A
A
La Rosée
P
P
Lahaye
T
T
Berger
U
U
Cross
N C
NC
Linkesch
W
W
Druker
B J
BJ
Hehlmann
R
R
Gambacorti- Passerini
C
C
Corneo
G
G
D'Incalci
M
M
D019943:Amino Acid Substitution; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D017354:Point Mutation; D016315:Proto-Oncogene Proteins c-abl / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D016315:Proto-Oncogene Proteins c-abl